CTOs on the Move

Harpoon Therapeutics

www.harpoontx.com

 
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.harpoontx.com
  • 611 Gateway Boulevard Suite 400
    South San Francisco, CA USA 94080
  • Phone: 650.443.7400

Executives

Name Title Contact Details

Funding

Harpoon Therapeutics raised $45M on 05/25/2017
Harpoon Therapeutics raised $70M on 11/12/2018

Similar Companies

Elevation Spine

Elevation Spine is a medical device company with a proprietary technology platform, Saber Technology, which is an advanced and differentiated approach to spinal fusion. The fusion procedure is highly efficient while remaining minimally invasive.

Stellar Pharmaceuticals Inc

Stellar Pharmaceuticals Inc is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clene

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Veranex

Veranex transforms your MedTech innovation with solutions for medical device, diagnostic, precision medicine, digital health, and drug delivery technologies.